Transparency, power, and influence in the pharmaceutical industry: policy gain or confidence game?
Gespeichert in:
| Weitere beteiligte Personen: | , , |
|---|---|
| Format: | Buch |
| Sprache: | Englisch |
| Veröffentlicht: |
Toronto ; Buffalo ; London
University of Toronto Press
[2021]
|
| Schlagwörter: | |
| Links: | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032797676&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| Abstract: | "There is plenty of controversy surrounding pharmaceuticals, however it cannot be denied that it is both a socially beneficial and profit-making industry. Regulators are expected to ensure that the economic success of the pharmaceutical industry does not come at the expense of public safety, yet, regulators have also assumed a cooperative role by providing advice on regulation and by targeting unmet medical needs. Concerns over regulatory standards, conflicts of interest, and the manipulation of information on drug safety and effectiveness have led to public mistrust, and a greater need for transparency between pharmaceutical industry and government regulators. Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry responsible for creating this sense of transparency in the industry, from development to market. The contributors to this volume examine the various mechanisms introduced to make the regulatory process more informative, and situate these efforts, within the larger project of enhancing the safety of drugs, vaccines, and other products."-- |
| Umfang: | VI, 296 Seiten |
| ISBN: | 9781487529031 9781487529048 |
Internformat
MARC
| LEADER | 00000nam a22000008c 4500 | ||
|---|---|---|---|
| 001 | BV047396485 | ||
| 003 | DE-604 | ||
| 005 | 20210927 | ||
| 007 | t| | ||
| 008 | 210802s2021 xx b||| 00||| eng d | ||
| 020 | |a 9781487529031 |c hbk |9 978-1-4875-2903-1 | ||
| 020 | |a 9781487529048 |c pbk |9 978-1-4875-2904-8 | ||
| 035 | |a (OCoLC)1269389345 | ||
| 035 | |a (DE-599)BVBBV047396485 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-473 | ||
| 082 | 0 | |a 362.17/82 |2 23 | |
| 084 | |a MF 9200 |0 (DE-625)122808: |2 rvk | ||
| 245 | 1 | 0 | |a Transparency, power, and influence in the pharmaceutical industry |b policy gain or confidence game? |c edited by Katherine Fierlbeck, Janice Graham, and Matthew Herder |
| 264 | 1 | |a Toronto ; Buffalo ; London |b University of Toronto Press |c [2021] | |
| 264 | 4 | |c ©2021 | |
| 300 | |a VI, 296 Seiten | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 520 | 3 | |a "There is plenty of controversy surrounding pharmaceuticals, however it cannot be denied that it is both a socially beneficial and profit-making industry. Regulators are expected to ensure that the economic success of the pharmaceutical industry does not come at the expense of public safety, yet, regulators have also assumed a cooperative role by providing advice on regulation and by targeting unmet medical needs. Concerns over regulatory standards, conflicts of interest, and the manipulation of information on drug safety and effectiveness have led to public mistrust, and a greater need for transparency between pharmaceutical industry and government regulators. Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry responsible for creating this sense of transparency in the industry, from development to market. The contributors to this volume examine the various mechanisms introduced to make the regulatory process more informative, and situate these efforts, within the larger project of enhancing the safety of drugs, vaccines, and other products."-- | |
| 650 | 0 | 7 | |a Regulierung |0 (DE-588)4201190-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 653 | 0 | |a Pharmaceutical policy / United States | |
| 653 | 0 | |a Pharmaceutical policy / European Union countries | |
| 653 | 0 | |a Pharmaceutical policy / Canada | |
| 653 | 0 | |a Pharmaceutical policy | |
| 653 | 2 | |a Canada | |
| 653 | 2 | |a European Union countries | |
| 653 | 2 | |a United States | |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 0 | 1 | |a Regulierung |0 (DE-588)4201190-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Fierlbeck, Katherine |0 (DE-588)171351274 |4 edt | |
| 700 | 1 | |a Graham, Janice Elizabeth |d 1958- |0 (DE-588)1235484637 |4 edt | |
| 700 | 1 | |a Herder, Matthew |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, PDF |z 978-1-4875-2905-5 |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, EPUB |z 978-1-4875-2906-2 |
| 856 | 4 | 2 | |m Digitalisierung UB Bamberg - ADAM Catalogue Enrichment |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032797676&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-032797676 | |
Datensatz im Suchindex
| _version_ | 1819312532701052928 |
|---|---|
| adam_text | Contents 1 Introduction 3 KATHERINE FIERLBECK, JANICE GRAHAM, AND MATTHEW HERDER 2 Transparency, Pharmaceudcals, and the Problem of Policy Change 13 KATHERINE FIERLBECK 3 Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View? 63 COURTNEY DAVIS, SHAI MULINARI, AND TOM JEFFERSON 4 The FDA and Health Canada: Similar Origins, yet Divergent Paths and Approaches to Transparency 95 MARGARET E. MCCARTHY AND JOSEPH S. ROSS 5 Clinical Trial Data Transparency in Canada: Mapping the Progress from Laggard to Leader 114 MARC-ANDRÉ GAGNON, MATTHEW HERDER, JANICE GRAHAM, KATHERINE FIERLBECK, AND ANNA DANYLIUK 6 The Limits of Transparency and the Role of Essential Medicines 129 NAV PERSAUD 7 Speak No Secrets: (Non) transparency in Health Canada’s Communications about Pharmaceutical Regulation 139 JOEL LEXCHIN 8 The Political Economy of Influence: Ghost-Management in the Pharmaceutical Sector 159 MARC-ANDRÉ GAGNON
Contents 9 Data Transparency and Rare Disease: Privacy versus Public Interest? 184 KANKSHA MAHADEVIA GHIMIRE AND TRUDO LEMMENS 10 The European Registration of the Pandemic Influenza Vaccine Pandemrix: A Case Study of the Consequences of Poor Clinical Data Transparency 219 TOM JEFFERSON 11 The Road Forward: How Researchers Can Sustain an Ethical and Transparent Health System 243 MTA BANZI 12 Conclusion 261 KATHERINE FIERLBECK, JANICE GRAHAM, AND MATTHEW HERDER Contributors 277 Index 281
|
| any_adam_object | 1 |
| author2 | Fierlbeck, Katherine Graham, Janice Elizabeth 1958- Herder, Matthew |
| author2_role | edt edt edt |
| author2_variant | k f kf j e g je jeg m h mh |
| author_GND | (DE-588)171351274 (DE-588)1235484637 |
| author_facet | Fierlbeck, Katherine Graham, Janice Elizabeth 1958- Herder, Matthew |
| building | Verbundindex |
| bvnumber | BV047396485 |
| classification_rvk | MF 9200 |
| ctrlnum | (OCoLC)1269389345 (DE-599)BVBBV047396485 |
| dewey-full | 362.17/82 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 362 - Social problems and services to groups |
| dewey-raw | 362.17/82 |
| dewey-search | 362.17/82 |
| dewey-sort | 3362.17 282 |
| dewey-tens | 360 - Social problems and services; associations |
| discipline | Soziologie Politologie |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03357nam a22005298c 4500</leader><controlfield tag="001">BV047396485</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20210927 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">210802s2021 xx b||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781487529031</subfield><subfield code="c">hbk</subfield><subfield code="9">978-1-4875-2903-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781487529048</subfield><subfield code="c">pbk</subfield><subfield code="9">978-1-4875-2904-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1269389345</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047396485</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-473</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">362.17/82</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MF 9200</subfield><subfield code="0">(DE-625)122808:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Transparency, power, and influence in the pharmaceutical industry</subfield><subfield code="b">policy gain or confidence game?</subfield><subfield code="c">edited by Katherine Fierlbeck, Janice Graham, and Matthew Herder</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Toronto ; Buffalo ; London</subfield><subfield code="b">University of Toronto Press</subfield><subfield code="c">[2021]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">VI, 296 Seiten</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">"There is plenty of controversy surrounding pharmaceuticals, however it cannot be denied that it is both a socially beneficial and profit-making industry. Regulators are expected to ensure that the economic success of the pharmaceutical industry does not come at the expense of public safety, yet, regulators have also assumed a cooperative role by providing advice on regulation and by targeting unmet medical needs. Concerns over regulatory standards, conflicts of interest, and the manipulation of information on drug safety and effectiveness have led to public mistrust, and a greater need for transparency between pharmaceutical industry and government regulators. Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry responsible for creating this sense of transparency in the industry, from development to market. The contributors to this volume examine the various mechanisms introduced to make the regulatory process more informative, and situate these efforts, within the larger project of enhancing the safety of drugs, vaccines, and other products."--</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Regulierung</subfield><subfield code="0">(DE-588)4201190-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmaceutical policy / United States</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmaceutical policy / European Union countries</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmaceutical policy / Canada</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmaceutical policy</subfield></datafield><datafield tag="653" ind1=" " ind2="2"><subfield code="a">Canada</subfield></datafield><datafield tag="653" ind1=" " ind2="2"><subfield code="a">European Union countries</subfield></datafield><datafield tag="653" ind1=" " ind2="2"><subfield code="a">United States</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Regulierung</subfield><subfield code="0">(DE-588)4201190-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fierlbeck, Katherine</subfield><subfield code="0">(DE-588)171351274</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Graham, Janice Elizabeth</subfield><subfield code="d">1958-</subfield><subfield code="0">(DE-588)1235484637</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Herder, Matthew</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, PDF</subfield><subfield code="z">978-1-4875-2905-5</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, EPUB</subfield><subfield code="z">978-1-4875-2906-2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Bamberg - ADAM Catalogue Enrichment</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032797676&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032797676</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV047396485 |
| illustrated | Not Illustrated |
| indexdate | 2024-12-20T19:18:21Z |
| institution | BVB |
| isbn | 9781487529031 9781487529048 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032797676 |
| oclc_num | 1269389345 |
| open_access_boolean | |
| owner | DE-473 DE-BY-UBG |
| owner_facet | DE-473 DE-BY-UBG |
| physical | VI, 296 Seiten |
| publishDate | 2021 |
| publishDateSearch | 2021 |
| publishDateSort | 2021 |
| publisher | University of Toronto Press |
| record_format | marc |
| spellingShingle | Transparency, power, and influence in the pharmaceutical industry policy gain or confidence game? Regulierung (DE-588)4201190-5 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd |
| subject_GND | (DE-588)4201190-5 (DE-588)4045696-1 (DE-588)4143413-4 |
| title | Transparency, power, and influence in the pharmaceutical industry policy gain or confidence game? |
| title_auth | Transparency, power, and influence in the pharmaceutical industry policy gain or confidence game? |
| title_exact_search | Transparency, power, and influence in the pharmaceutical industry policy gain or confidence game? |
| title_full | Transparency, power, and influence in the pharmaceutical industry policy gain or confidence game? edited by Katherine Fierlbeck, Janice Graham, and Matthew Herder |
| title_fullStr | Transparency, power, and influence in the pharmaceutical industry policy gain or confidence game? edited by Katherine Fierlbeck, Janice Graham, and Matthew Herder |
| title_full_unstemmed | Transparency, power, and influence in the pharmaceutical industry policy gain or confidence game? edited by Katherine Fierlbeck, Janice Graham, and Matthew Herder |
| title_short | Transparency, power, and influence in the pharmaceutical industry |
| title_sort | transparency power and influence in the pharmaceutical industry policy gain or confidence game |
| title_sub | policy gain or confidence game? |
| topic | Regulierung (DE-588)4201190-5 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd |
| topic_facet | Regulierung Pharmazeutische Industrie Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032797676&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT fierlbeckkatherine transparencypowerandinfluenceinthepharmaceuticalindustrypolicygainorconfidencegame AT grahamjaniceelizabeth transparencypowerandinfluenceinthepharmaceuticalindustrypolicygainorconfidencegame AT herdermatthew transparencypowerandinfluenceinthepharmaceuticalindustrypolicygainorconfidencegame |